Cost effectiveness of aggressive care for patients with nontraumatic coma

Mary Beth Hamel, Russell Phillips, Joan Teno, Roger B. Davis, Lee Goldman, Joanne Lynn, Norman Desbiens, Alfred F. Connors, Joel Tsevat

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objective: To estimate the cost effectiveness of aggressive care for patients with nontraumatic coma. Design: Cost-effectiveness analysis. Setting: Five academic medical centers. Patients: Patients with nontraumatic coma enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT). Patients with reversible metabolic causes of coma such as diabetic ketoacidosis or uremia were excluded. Measurements: We calculated the incremental cost effectiveness of continuing aggressive care vs. withholding cardiopulmonary resuscitation and ventilatory support after day 3 of coma. We estimated life expectancy based on up to 4.6 yrs of follow-up. Utilities (quality-of-life weights) were estimated using time-tradeoff questions. Costs were based on hospital fiscal data and Medicare data. Separate analyses were conducted for two prognostic groups based on five risk factors assessed on day 3 of coma: age ≥70 yrs, abnormal brainstem response, absent verbal response, absent withdrawal to pain, and serum creatinine ≥132.6 μmol/L (1.5 mg/dL). Results: For the 596 patients studied, the median (25th, 75th percentile) age was 67 yrs (range, 55-77), and 52% were female. By 2 months after enrollment, 69% had died, 19% were severely disabled, 7% had survived without severe disability, and 4% had survived with unknown functional status. The incremental cost effectiveness of the more aggressive care strategy was $140,000 (1998 dollars) per quality-adjusted life year (QALY) for high-risk patients (3-5 risk factors, 93% 2-month mortality) and $87,000/QALY for low-risk patients (0-2 risk factors, 49% mortality). In sensitivity analyses, the incremental cost per QALY did not fall below $50,000/QALY, even with wide variation in our baseline estimates. Conclusions: Continuing aggressive care after day 3 of non-traumatic coma is associated with a high cost per QALY gained, especially for patients at high risk for poor outcomes. Earlier decisions to withhold life-sustaining treatments for patients with very poor prognoses may yield considerable cost savings.

Original languageEnglish (US)
Pages (from-to)1191-1196
Number of pages6
JournalCritical care medicine
Volume30
Issue number6
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Coma
Cost-Benefit Analysis
Patient Care
Quality-Adjusted Life Years
Costs and Cost Analysis
Resuscitation Orders
Diabetic Ketoacidosis
Mortality
Cost Savings
Uremia
Cardiopulmonary Resuscitation
Medicare
Life Expectancy
Brain Stem
Creatinine
Quality of Life
Weights and Measures
Pain
Serum

Keywords

  • Coma
  • Cost effectiveness
  • Costs cardiopulmonary resuscitation
  • Medical decision making
  • Outcomes

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Hamel, M. B., Phillips, R., Teno, J., Davis, R. B., Goldman, L., Lynn, J., ... Tsevat, J. (2002). Cost effectiveness of aggressive care for patients with nontraumatic coma. Critical care medicine, 30(6), 1191-1196. https://doi.org/10.1097/00003246-200206000-00002

Cost effectiveness of aggressive care for patients with nontraumatic coma. / Hamel, Mary Beth; Phillips, Russell; Teno, Joan; Davis, Roger B.; Goldman, Lee; Lynn, Joanne; Desbiens, Norman; Connors, Alfred F.; Tsevat, Joel.

In: Critical care medicine, Vol. 30, No. 6, 01.01.2002, p. 1191-1196.

Research output: Contribution to journalArticle

Hamel, MB, Phillips, R, Teno, J, Davis, RB, Goldman, L, Lynn, J, Desbiens, N, Connors, AF & Tsevat, J 2002, 'Cost effectiveness of aggressive care for patients with nontraumatic coma', Critical care medicine, vol. 30, no. 6, pp. 1191-1196. https://doi.org/10.1097/00003246-200206000-00002
Hamel, Mary Beth ; Phillips, Russell ; Teno, Joan ; Davis, Roger B. ; Goldman, Lee ; Lynn, Joanne ; Desbiens, Norman ; Connors, Alfred F. ; Tsevat, Joel. / Cost effectiveness of aggressive care for patients with nontraumatic coma. In: Critical care medicine. 2002 ; Vol. 30, No. 6. pp. 1191-1196.
@article{d2e1719b9c014515b6c9bd30b0270a8d,
title = "Cost effectiveness of aggressive care for patients with nontraumatic coma",
abstract = "Objective: To estimate the cost effectiveness of aggressive care for patients with nontraumatic coma. Design: Cost-effectiveness analysis. Setting: Five academic medical centers. Patients: Patients with nontraumatic coma enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT). Patients with reversible metabolic causes of coma such as diabetic ketoacidosis or uremia were excluded. Measurements: We calculated the incremental cost effectiveness of continuing aggressive care vs. withholding cardiopulmonary resuscitation and ventilatory support after day 3 of coma. We estimated life expectancy based on up to 4.6 yrs of follow-up. Utilities (quality-of-life weights) were estimated using time-tradeoff questions. Costs were based on hospital fiscal data and Medicare data. Separate analyses were conducted for two prognostic groups based on five risk factors assessed on day 3 of coma: age ≥70 yrs, abnormal brainstem response, absent verbal response, absent withdrawal to pain, and serum creatinine ≥132.6 μmol/L (1.5 mg/dL). Results: For the 596 patients studied, the median (25th, 75th percentile) age was 67 yrs (range, 55-77), and 52{\%} were female. By 2 months after enrollment, 69{\%} had died, 19{\%} were severely disabled, 7{\%} had survived without severe disability, and 4{\%} had survived with unknown functional status. The incremental cost effectiveness of the more aggressive care strategy was $140,000 (1998 dollars) per quality-adjusted life year (QALY) for high-risk patients (3-5 risk factors, 93{\%} 2-month mortality) and $87,000/QALY for low-risk patients (0-2 risk factors, 49{\%} mortality). In sensitivity analyses, the incremental cost per QALY did not fall below $50,000/QALY, even with wide variation in our baseline estimates. Conclusions: Continuing aggressive care after day 3 of non-traumatic coma is associated with a high cost per QALY gained, especially for patients at high risk for poor outcomes. Earlier decisions to withhold life-sustaining treatments for patients with very poor prognoses may yield considerable cost savings.",
keywords = "Coma, Cost effectiveness, Costs cardiopulmonary resuscitation, Medical decision making, Outcomes",
author = "Hamel, {Mary Beth} and Russell Phillips and Joan Teno and Davis, {Roger B.} and Lee Goldman and Joanne Lynn and Norman Desbiens and Connors, {Alfred F.} and Joel Tsevat",
year = "2002",
month = "1",
day = "1",
doi = "10.1097/00003246-200206000-00002",
language = "English (US)",
volume = "30",
pages = "1191--1196",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Cost effectiveness of aggressive care for patients with nontraumatic coma

AU - Hamel, Mary Beth

AU - Phillips, Russell

AU - Teno, Joan

AU - Davis, Roger B.

AU - Goldman, Lee

AU - Lynn, Joanne

AU - Desbiens, Norman

AU - Connors, Alfred F.

AU - Tsevat, Joel

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Objective: To estimate the cost effectiveness of aggressive care for patients with nontraumatic coma. Design: Cost-effectiveness analysis. Setting: Five academic medical centers. Patients: Patients with nontraumatic coma enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT). Patients with reversible metabolic causes of coma such as diabetic ketoacidosis or uremia were excluded. Measurements: We calculated the incremental cost effectiveness of continuing aggressive care vs. withholding cardiopulmonary resuscitation and ventilatory support after day 3 of coma. We estimated life expectancy based on up to 4.6 yrs of follow-up. Utilities (quality-of-life weights) were estimated using time-tradeoff questions. Costs were based on hospital fiscal data and Medicare data. Separate analyses were conducted for two prognostic groups based on five risk factors assessed on day 3 of coma: age ≥70 yrs, abnormal brainstem response, absent verbal response, absent withdrawal to pain, and serum creatinine ≥132.6 μmol/L (1.5 mg/dL). Results: For the 596 patients studied, the median (25th, 75th percentile) age was 67 yrs (range, 55-77), and 52% were female. By 2 months after enrollment, 69% had died, 19% were severely disabled, 7% had survived without severe disability, and 4% had survived with unknown functional status. The incremental cost effectiveness of the more aggressive care strategy was $140,000 (1998 dollars) per quality-adjusted life year (QALY) for high-risk patients (3-5 risk factors, 93% 2-month mortality) and $87,000/QALY for low-risk patients (0-2 risk factors, 49% mortality). In sensitivity analyses, the incremental cost per QALY did not fall below $50,000/QALY, even with wide variation in our baseline estimates. Conclusions: Continuing aggressive care after day 3 of non-traumatic coma is associated with a high cost per QALY gained, especially for patients at high risk for poor outcomes. Earlier decisions to withhold life-sustaining treatments for patients with very poor prognoses may yield considerable cost savings.

AB - Objective: To estimate the cost effectiveness of aggressive care for patients with nontraumatic coma. Design: Cost-effectiveness analysis. Setting: Five academic medical centers. Patients: Patients with nontraumatic coma enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT). Patients with reversible metabolic causes of coma such as diabetic ketoacidosis or uremia were excluded. Measurements: We calculated the incremental cost effectiveness of continuing aggressive care vs. withholding cardiopulmonary resuscitation and ventilatory support after day 3 of coma. We estimated life expectancy based on up to 4.6 yrs of follow-up. Utilities (quality-of-life weights) were estimated using time-tradeoff questions. Costs were based on hospital fiscal data and Medicare data. Separate analyses were conducted for two prognostic groups based on five risk factors assessed on day 3 of coma: age ≥70 yrs, abnormal brainstem response, absent verbal response, absent withdrawal to pain, and serum creatinine ≥132.6 μmol/L (1.5 mg/dL). Results: For the 596 patients studied, the median (25th, 75th percentile) age was 67 yrs (range, 55-77), and 52% were female. By 2 months after enrollment, 69% had died, 19% were severely disabled, 7% had survived without severe disability, and 4% had survived with unknown functional status. The incremental cost effectiveness of the more aggressive care strategy was $140,000 (1998 dollars) per quality-adjusted life year (QALY) for high-risk patients (3-5 risk factors, 93% 2-month mortality) and $87,000/QALY for low-risk patients (0-2 risk factors, 49% mortality). In sensitivity analyses, the incremental cost per QALY did not fall below $50,000/QALY, even with wide variation in our baseline estimates. Conclusions: Continuing aggressive care after day 3 of non-traumatic coma is associated with a high cost per QALY gained, especially for patients at high risk for poor outcomes. Earlier decisions to withhold life-sustaining treatments for patients with very poor prognoses may yield considerable cost savings.

KW - Coma

KW - Cost effectiveness

KW - Costs cardiopulmonary resuscitation

KW - Medical decision making

KW - Outcomes

UR - http://www.scopus.com/inward/record.url?scp=0036277455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036277455&partnerID=8YFLogxK

U2 - 10.1097/00003246-200206000-00002

DO - 10.1097/00003246-200206000-00002

M3 - Article

VL - 30

SP - 1191

EP - 1196

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 6

ER -